Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Regeneron Pharmaceuticals, Inc. (REGN) Profile & Business Summary
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Key Information
| Ticker | REGN |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.regeneron.com |
Market Trend Overview for REGN
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-01 (ET)
As of 2026-10-01, REGN is breaking down after a failed trend. Over the longer term, the trend remains bullish.
REGN last closed at 734.81. The price is about 3.1 ATR below its recent average price (788.10), and the market is currently in a breakdown after a failed trend. Price at 734.81 has weakened below prior structure. Next minor support lies near 648.66, while resistance is around 815.80. View Support & Resistance from Options
The prior trend has broken down. Downside risk is higher, and the market may need time to stabilize before a new direction forms.
Trend score: 20 out of 100. Overall alignment is weak. The market is currently in a breakdown following a failed trend. Trend alignment is weak, and recent signals suggest the structure may be breaking down.
Price is stretched well below its recent average (about 3.1 ATR). Downside extension is elevated, and chasing weakness here carries a higher rebound risk.
There is no clear key risk boundary right now.
On 2026-09-09, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-09-11] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
The model does not deploy the setup because the current position looks stretched and more vulnerable to pullback or digestion.
The model does not deploy this setup because extension risk is 81%, pullback risk is 56%, entry geometry is unfavorable at the current location, and recent price behavior has shown failed reversal memory. Predictability is 47%, agreement is 93%, and reversal risk is 33%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 50 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-01. The current price is 734.81, 5.22% below the estimated average cost of 775.28. An estimated 16.7% of recent positioning is below the current price, while 83.1% is above it. The peak-density price is 807.00. The largest concentrated cost region is 780.75 to 816.75 and contains 39.2% of the estimated distribution. The nearest region below the current price is 694.75 to 697.25. The nearest region above the current price is 735.75 to 736.25.
Short Interest & Covering Risk for REGN
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is relatively low, indicating limited pressure from short positions. (Historical percentile: 0%)
Structure Analysis
REGN Short positioning looks normal. Current days to cover is 4.4 trading days, meaning short positions would unwind somewhat slower than average. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -13.8%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. Average trading volume is weakening, indicating contracting liquidity. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.